Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Definium Therapeutics (NASDAQ:DFTX) had its price objective hoisted by investment analysts at HC Wainwright from $55.00 to $70.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 301.15% from the company’s current price.

Several other equities research analysts also recently commented on DFTX. Royal Bank Of Canada upped their price objective on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Needham & Company LLC reissued a “buy” rating on shares of Definium Therapeutics in a research report on Monday, January 5th. Canaccord Genuity Group raised their price objective on shares of Definium Therapeutics from $16.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Robert W. Baird set a $37.00 target price on shares of Definium Therapeutics in a report on Thursday, January 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $35.70.

Definium Therapeutics Stock Performance

NASDAQ:DFTX opened at $17.45 on Monday. Definium Therapeutics has a 1 year low of $4.70 and a 1 year high of $18.70. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.29 and a quick ratio of 6.29. The business has a fifty day simple moving average of $15.66 and a two-hundred day simple moving average of $12.84. The company has a market capitalization of $1.72 billion, a P/E ratio of -8.19 and a beta of 2.56.

Insider Activity at Definium Therapeutics

In other Definium Therapeutics news, insider Daniel Karlin sold 5,600 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $73,640.00. Following the completion of the transaction, the insider owned 425,025 shares of the company’s stock, valued at $5,589,078.75. The trade was a 1.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark Sullivan sold 11,276 shares of the company’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $148,279.40. Following the completion of the transaction, the insider owned 282,576 shares of the company’s stock, valued at $3,715,874.40. This trade represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 42,667 shares of company stock valued at $561,071. Company insiders own 2.26% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Stoneridge Investment Partners LLC boosted its holdings in shares of Definium Therapeutics by 7.5% in the 3rd quarter. Stoneridge Investment Partners LLC now owns 11,563 shares of the company’s stock worth $136,000 after purchasing an additional 804 shares in the last quarter. Cerity Partners LLC lifted its position in Definium Therapeutics by 2.4% in the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock worth $322,000 after buying an additional 1,165 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in Definium Therapeutics by 9.4% in the second quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company’s stock worth $106,000 after buying an additional 1,400 shares in the last quarter. Creative Planning grew its position in Definium Therapeutics by 2.6% during the second quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after acquiring an additional 1,655 shares during the last quarter. Finally, CWM LLC raised its stake in shares of Definium Therapeutics by 67.4% during the second quarter. CWM LLC now owns 4,459 shares of the company’s stock worth $29,000 after acquiring an additional 1,796 shares in the last quarter. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.